1 – 22 of 22
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Delays in dealing with complaints against drug companies are growing, BMJ finds
(
- Contribution to specialist publication or newspaper › Specialist publication article
- 2023
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
(
- Contribution to journal › Article
-
Mark
Authors’ reply to Fell
(
- Contribution to journal › Letter
-
Mark
Pharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
(
- Contribution to journal › Article
-
Mark
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
(
- Contribution to journal › Article
- 2022
-
Mark
Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
(
- Contribution to journal › Article
-
Mark
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
(
- Contribution to journal › Article
-
Mark
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
(
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
(
- Contribution to journal › Article
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Is there evidence for the racialization of pharmaceutical regulation? : Systematic comparison of new drugs approved over five years in the USA and the EU
(
- Contribution to journal › Article
-
Mark
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
- 2020
-
Mark
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
(
- Contribution to journal › Article
-
Mark
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
2020) In PLoS ONE(
- Contribution to journal › Article
- 2019
-
Mark
Exposing drug industry funding of UK patient organisations
(
- Contribution to journal › Article
-
Mark
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
(
- Contribution to journal › Article
-
Mark
The whistleblowing drama behind Astellas’s suspension from the ABPI
(
- Contribution to journal › Letter
-
Mark
Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
(
- Contribution to journal › Article
- 2018
-
Mark
Disclosure of payments by pharmaceutical companies to healthcare professionals in the United Kingdom: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
(
- Contribution to journal › Article